Harrow, Inc.
Moat Score — Harrow, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Harrow's branded ophthalmic drug approvals and ImprimisRx's 503A/503B facility registrations are real regulatory assets, but the portfolio is a collection of licensed/acquired products rather than deep internally-generated proprietary IP. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | ImprimisRx's cash-pay compounding model avoids PBM and formulary negotiation costs that burden many branded drugmakers, giving Harrow a structurally different, somewhat favorable cost position in that channel specifically. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Cash-pay compounding lets Harrow set prices directly with prescribers and patients outside insurance negotiation, but the branded portfolio faces normal payer and generic pricing pressure, and Harrow itself says it is smaller than competitors with less resource to defend pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Neither branded pharmaceutical sales nor compounding pharmacy services exhibit a network effect; one prescriber's use of Harrow's products does not increase value for another prescriber. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | ImprimisRx's 10,000+ prescriber relationships and familiarity with specific compounded formulations create some retention, but prescribers can switch to another 503A/503B compounder or an FDA-approved alternative without major friction. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | At 382 employees and a mid-sized specialty pharma scale, Harrow explicitly acknowledges it is smaller than larger branded ophthalmology competitors, limiting the efficient-scale advantages a bigger rival would have. |